High HSP70-membrane expression on leukemic cells from patients with acute myeloid leukemia is associated with a worse prognosis Acute myeloid leukemia (AML) results in an accumulation of blasts with a variable degree of myeloid differentiation. Heatshock proteins belong to a group of highly conserved proteins that are predominantly synthesized following stress and fulfill important functions including transport of proteins across membranes, protein repair or degradation. Under physiological conditions, heat-shock proteins also serve as molecular chaperones during cellular differentiation. Their main function is to prevent unfolded proteins from aggregation. 1 Following stress, HSP70 is highly expressed in normal cells and cancer cells, including leukemic cells. HSP70 is involved in inhibiting apoptosis by binding to the tumor suppressor gene product p53 or interaction with apoptosis-inducing factor. Within the last years, it became obvious that HSP70 is also present on the plasma membrane of tumor cells but not on the corresponding normal tissues. 1 Depending on their intra-or extracellular localization, HSP70 mediates either protective or immune stimulatory functions. We investigated the membrane expression of HSP70 on AML blasts obtained from 92 patients (pts) with different subtypes at initial diagnosis as well as from eight patients in complete remission (CR), 14 pts in relapse and five patients with persisting disease to enlighten its prognostic relevance in AML.
Twenty-seven patients had presented with an undifferentiated leukemia (M0: n ¼ 5; M1: n ¼ 22), 38 pts with an immature granulocytic leukemia (M2: n ¼ 29; M3: n ¼ 9) and 37 pts with a monocytic leukemia (M4: n ¼ 25; M5: n ¼ 12). Seventeen patients were not French-American-British (FAB) classified. In 95 pts a pAML, and in 22 pts a sAML was diagnosed. The samples contained on average 81% blast cells. Patients studied during the course of AML had been treated according to standard treatment protocols.
Mononuclear cells were derived from aspirated bone marrow (BM) cells by Ficoll density gradient centrifugation. The mouse monoclonal antibody cmHSP70.1 conjugated with fluorescein isothiocyanate was used for the detection of HSP70 on viable cells (multimmune GmbH, Regensburg, Germany) in combination with phycoerythrin-, antigen-presenting cell-or PerCPconjugated antibodies (Beckmann-Coulter, Krefeld, Germany) directed against leukemic antigens. In cases with a high tumor load, panmyeloid markers like CD33, CD13 or CD34 in CD34 þ leukemia were used. The samples were analyzed on a FACScan (Becton Dickinson, BD, Heidelberg, Germany). Positive HSP70 expression on leukemic cells was considered in cases in which more than 10% of cells in a gate surrounding blasts, residual lymphocytes and monocytes could be identified that coexpressed HSP70 and an AML-specific marker. 2 The cytogenetic results were interpreted according to the International system of Human Cytogenetic Nomenclature. A 'favorable risk' abnormality was defined by the presence of t(8;21), t(15;17) or inv/t (16). A 'poor risk' abnormality was considered in patients with del/t 11q23 aberrations, À5/5qÀ, À7/7qÀ, 3q21 aberrations, t(6;9) or a complex karyotype (three or more numerical and/or structural abnormalities). An 'intermediate risk' was considered in patients with a normal karyotype and in patients with the remaining abnormalities. 3 Mean and s.d., median and range, two-tailed t-tests and w 2 -tests were performed using Excel 97. A 'walking cutoff' was run from the lowest to the highest level of HSP70 expression on leukemic cells. Thus, for each cutoff value the patient's samples were subdivided into two groups, with values below or above the particular cutoff, as described. 3 For each of these separations, the log-rank test was performed comparing the length of progress-free survival in the respective groups. Each test yielded a w 2 -value, representative for the difference in progress-free survival. The w 2 -value is dependent on the number of patients in each group, such that highly unequal numbers of patients in each group yield smaller w 2 -values than do groups of patients with similar numbers, even when the difference in mean survival times remains unchanged. The HSP70 cutoff value yielding the largest w 2 -value was chosen for analysis. They represent the values with maximum probability for relevant differentiation between cases with shorter/ longer time of progression-free survival. After evaluation of the cutoff values, corresponding progression-free survival times were evaluated and displayed according to Kaplan-Meier. For relapse-free survival analyses, patients were censored at the time of BM transplantation.
In our patient's cohort, 55% of the investigated AML samples were HSP70
þ defined by more than 10% cells in the gate coexpressing leukemic and HSP70 antigen. Defining 'positivity' as more than background positivity found in healthy BM controls evaluated by isotype-matched evaluations, we could already show that 75% of AML samples were HSP70 þ . 2, 4 We could not detect significant differences in the different FAB subtypes, although a higher HSP70 expression was seen in cases with prognostically unfavorable subtypes ( Figure 1 ). No differences in the expression were seen between the FAB subtypes M4eo and M4 or the other subtypes or between cases with p or sAML (data not shown). In healthy samples, less than 5% HSP70 þ cells were found.
Moreover, we could not detect a significant correlation between HSP70 expression and cytogenetic risk groups Ic immunocytologically determined m±SD mean±standard deviation
Figure 3
Expression of HSP70 in patients at diagnosis, in CR, during persisting disease or at relapse. Mononuclear BM cells from AML patients at first diagnosis were analyzed by FACS analysis using an FITC-conjugated antibody cmHSP70.1 in combination with a PE-, APC-or PerCP-conjugated antibody directed against a leukemic antigen. The mean percentages of positive cases or cells in the gate for the respective markers are presented with AML cases subdivided in cases studied in different stages of the disease.
(P ¼ 0.53), although more HSP70 þ cells were seen in the 'poor' risk group -despite less 'immunocytologically' detectable blasts in the poor risk group (Figure 2 ). This could mean that an analysis of more cases with matched blast counts could lead to significant results. No other study has yet examined HSP70 expression in correlation with FAB types or cytogenetic risk groups. Patients in CR (n ¼ 8) expressed HSP70 to a lower degree (6% HSP70 þ cells) than patients at relapse (n ¼ 14) or with persisting disease (n ¼ 5; 26 and 13% positive cells), thereby confirming preliminary data of our group (Figure 3) .
Compared to active stages of the disease, we detected that AML patients in CR showed a lower cellular expression of HSP70 þ cells. As HSP70 is selectively expressed on leukemic but not on healthy BM cells, 2, 4 it qualifies as a 'tumor marker'. The expression profile of HSP70 on leukemic cells has to be evaluated at initial diagnosis to monitor an increase or decrease of leukemic cells in the course of the disease. If HSP70 is a suitable marker to detect minimal residual disease has to be evaluated in further studies. Therefore a representative number of AML patients has to be investigated and monitored during the course of CR. A comparison of the expression of HSP70 between the 'responder' and 'non-responder' group to chemotherapy did not yield significant differences. However, we could show that patients, who went into remission and who expressed more than 33.0% HSP70 þ blasts -with this cutoff value being evaluated by a walking cutoff analysis -had a significantly shorter relapsefree survival time compared with the cases with a lower amount than 33.0% HSP70 þ blasts (P ¼ 0.04). Although the mean time of progress-free survival of the patients with less than 33.0% HSP70 þ cells was 20.1 months, patients with more than 33.0% HSP70 þ cells were characterized by a mean time of progressfree survival of 6.4 months (Figure 4) . A possible explanation of this could be -as shown in another study 5 -that HSP70 endosomal and lysosomal membrane expression can mediate resistance to apoptosis by inhibiting death-associated lysosomal membrane permeabilization. Patients with a higher amount of HSP70 þ blasts may have a shorter relapse-free survival because their leukemic blasts are more resistant to apoptosis. Additionally, it could be observed that the patient group with more HSP70 þ -expressing cells contained no patient with a favorable risk or with the FAB-type M3, whose patients generally present with a good prognosis. So possibly, there is a relation between higher HSP70 expression and patients with worse prognosis, as is already shown in other studies that high HSP70 expression correlates with poor prognosis in solid tumors like breast, endometrial, uterine cervical, colorectal or hepatocellular carcinoma. [5] [6] [7] Another study also showed that patients with a lower HSP70 expression had higher CR rates as well as a significantly longer median overall survival. 8 The cutoff values we analyzed were not yet evaluated in other studies. Possibly, the amount of HSP70 expression could help to develop treatment strategies for individual patients considering their prognostic risk.
Earlier studies showed that HSP70 is a target for natural killer cells and expressed on the surface of tumor cells and mediate an increased sensitivity to allogeneic natural killer cells. 2, 9 Natural killer cells activated with a low dose of interleukin 2 and recombinant HSP70 can reveal a cytotoxic response against autologous HSP70 þ leukemic blasts. 4, 9 This HSP70-targeted therapy could be of value, especially for patients who express HSP70 in a high degree. To evaluate the efficacy of such an HSP70-targeted therapy, clinical trials are needed. Taken together, further prospective studies with a more representative number of patients should be performed and analyzed in multivariate models to evaluate the prognostic impact of a HSP70 expression in AML. Correlation of proportions of HSP70-positive cells with progression of the disease. Mononuclear BM cells from AML patients at first diagnosis were analyzed by FACS analysis using an FITCconjugated antibody cmHSP70.1 in combination with a PE-, APC-or PerCP-conjugated antibody directed against a leukemic antigen. Cases expressing HSP70 were separated each in two prognostic groups evaluating a cutoff value for the largest w 2 -value representing the value of maximum probability with a most significant differentiation between cases with a shorter or longer relapse-free survival time.
Patients' characteristics of the groups compared, Kaplan-Meier plots and the respective P-value calculated by log-rank test are given.
